<DOC>
	<DOCNO>NCT02328391</DOCNO>
	<brief_summary>OBJECTIVE study effectiveness administration Erlotinib 150 mg/Day v.o . second-line treatment patient lung cancer advance non-small histology predominantly flaky assess survival free progression ( SLP ) . Design Studio postautoritation multicenter observational follow-up prospective ( EPA-SP ) type . DISEASE OTRASTORNO A study cell Lung Cancer small ( NSCLC ) . MEDICATION object data study drug study erlotinib . -Dose treatment guideline follow correspond product sheet . Management dosage adverse effect specify point H. 15 Protocol . POPULATION study number TOTAL subject population study : adult patient diagnosis NSCLC predominantly squamous histology total number subject : participation approximately 51 patient expected DISEASE OR DISORDER TO STUDY Non Small Cell Lung Cancer ( NSCLC ) . MEDICATION DATA OBJECT OF STUDY The drug study erlotinib . -Dose treatment guideline Follow correspond product sheet . Management dosage adverse effect specify point H. 15 Protocol . STUDY POPULATION AND NUMBER TOTAL OF SUBJECTS Study : adult patient diagnosis NSCLC predominantly squamous histology total number subject : participation approximately 51 patient expect .</brief_summary>
	<brief_title>STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>• Age ≥ 18 year . Histological cytologic diagnosis cancer ( NSCLC ) predominantly squamous histology stage IV nonsmallcell lung . ECOG performance status 0 2 . Patients progress first line advance disease eligible second line Erlotinib . Patients grant inform , preferably write , oral consent witness independent research team . • Patients uncontrolled severe systemic disease , active infection , neoplasia concomitant secondary neoplasia primary disease , except carcinoma situ cervix adequately treat skin carcinoma . Disease mutate EGFR , accord local laboratory . The determination EGFR mandatory . Those patient center determination EGFR patient EGFR unknown may include . Inability take oral medication previous surgical procedure affect absorption imply need intravenous parenteral feeding . Interstitial lung disease clinically active . Unstable angina recent myocardial infarction . Brain metastasis uncontrolled progressive . Patients participate clinical trial . Use inhibitor tyrosine kinase first line treatment . Patients whose estimated life expectancy reach 2 month . Any condition , situation , opinion investigator , may endanger safety patient , could interfere significantly involvement subject study evaluation result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>